Showing results (61-70 of 70) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular TrapsAlvaro Teijeira, Saray Garasa, Maria C Ochoa, et al.Nature Medicine|February 12, 2019
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastomaKurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, et al.Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.The Journal of Clinical Investigation|May 1, 2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancerAlvaro Lopez-Janeiro, José González-Gomariz, Fadi Issa, et al.Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.Cancer Research Communications|February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsValentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.Science Translational Medicine|October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumorsIván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.Nature|April 24, 2024
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicaseKristen A Baltgalvis, Kelsey N Lamb, Kent T Symons, et al.Pageof 7